Latest Breaking News On - Anti sortilin antibody - Page 1 : comparemela.com

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

AL101 is being developed to elevate progranulin levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated. | November 29, 2022

United statesSouth san franciscoSan franciscoDan budwickLaura perry carrie mckimGary romanoAlector incExchange commissionDrug administrationClinical trialsChief medical officerDosing dataPacific standard timeAnti sortilin antibodyPrivate securities litigation reform actQuarterly report

Alector (ALEC) Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

Alector (ALEC) Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesGary romanoAlector incClinical trialsChief medical officerDosing dataPacific standard timePresentation detailsposter numberAnti sortilin antibody